Child Neurology Society's Brainstorm cover image

CNS Brainstorm Episode 48 "Pediatric NF1 Therapeutics" with guest Bonnie Kaur, MD

Child Neurology Society's Brainstorm

00:00

Who is eligible for MEK inhibitors

Bonnie Kaur summarizes FDA approvals: treat any patient >1 year (selumetinib) or >2 years (mirdametinib) with inoperable symptomatic plexiform NF.

Play episode from 03:10
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app